Effects of aldosterone and related steroids on LPS-induced increased expression of inducible NOS in rat aortic smooth muscle cells

British Journal of Pharmacology

Volumn 164, Issue 8, 2011, Pages 2003-2014

  Godfrey, V ^a   Martin, A L ^a,b   Struthers, A D ^a   Lyles, G A ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

aldosterone; eplerenone; lipopolysaccharide; mifepristone; nitric oxide; nitric oxide synthase; rat aorta; smooth muscle cells; spironolactone; steroid receptors

Indexed keywords

ALDOSTERONE; CELL PROTEIN; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; EPLERENONE; GESTAGEN; GLUCOCORTICOID RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MIFEPRISTONE; NITRITE; PROGESTERONE; SPIRONOLACTONE; STEROID RECEPTOR;

ANIMAL CELL; ANIMAL CELL CULTURE; AORTA MEDIA; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; IMMUNOBLOTTING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; SMOOTH MUSCLE FIBER; WESTERN BLOTTING;

EID: 81855228882     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01523.x     Document Type: Article

References (42)

1. Aktan F, (2004). iNOS-mediated nitric oxide production and its regulation. Life Sci 75: 639-653. (Pubitemid 38686696)
2. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 158 (Suppl. 1): S1-S254.
3. Beasley D, Eldridge M, (1994). Interleukin-1β and tumor necrosis factor-α synergistically induce NO synthase in rat vascular smooth muscle cells. Am J Physiol 266: R1197-R1203.
4. Bendtzen K, Hansen PR, Rieneck K, (2003). Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clin Exp Immunol 134: 151-158. (Pubitemid 37186601)
5. Cachofeiro V, Miana M, de las Heras N, Martín-Fernández B, Ballesteros S, Fernández-Tresguerres J, et al,. (2008). Aldosterone and the vascular system. J Steroid Biochem Mol Biol 109: 331-335.
6. Cadepond F, Ulman A, Baulieu E-E, (1997). RU 486 (MIFEPRISTONE): mechanisms of action and clinical uses. Annu Rev Med 48: 129-156. (Pubitemid 27101820)
7. Chai W, Garrelds IM, de Vries R, Batenburg WW, van Kats JP, Danser AHJ, (2005). Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II. Hypertension 46: 701-706. (Pubitemid 43186741)
8. Chou TC, Yang SP, Pei D, (2002). Amlodipine inhibits pro-inflammatory cytokines and free radical production and nitric oxide synthase expression in lipopolysaccharide/interferon-gamma-stimulated cultured vascular smooth muscle cells. Jpn J Pharmacol 89: 157-163. (Pubitemid 34752301)
9. Chun T-Y, Bloem LJ, Pratt JH, (2003). Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes. Endocrinology 144: 1712-1717. (Pubitemid 36543307)
10. Connell JMC, Davies E, (2005). The new biology of aldosterone. J Endocrinol 186: 1-20. (Pubitemid 41015660)
11. Dudzinski DM, Igarashi J, Greif D, Michel T, (2006). The regulation and pharmacology of endothelial nitric oxide synthases. Annu Rev Pharmacol Toxicol 46: 235-276. (Pubitemid 43271190)
12. Farman N, Bocchi B, (2000). Mineralocorticoid selectivity: molecular and cellular aspects. Kidney Int 57: 1364-1369. (Pubitemid 30207892)
13. Garthwaite SM, McMahon SG, (2004). The evolution of aldosterone antagonists. Mol Cell Endocrinol 217: 27-31. (Pubitemid 38596625)
14. Ginnan R, Guikema BJ, Halligan KE, Singer HA, Jourd'heuil D, (2008). Regulation of smooth muscle by inducible nitric oxide synthase and NADPH oxidase in vascular proliferative tissues. Free Radic Biol Med 44: 1232-1245.
15. Harizi H, Mormède P, Corcuff J-B, (2008). Inter-strain differences in glucocorticoid and mineralocorticoid effects on macrophage and lymphocyte functions in mice. J Neuroimmunol 204: 38-42.
16. Ikeda U, Kanbe T, Nakayama I, Kawahara Y, Yokoyama M, Shimada K, (1995). Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1β. Eur J Pharmacol 290: 69-73.
17. Katsuyama K, Shichiri M, Kato H, Imai T, Marumo F, Hirata Y, (1999). Differential inhibitory actions by glucocorticoid and aspirin on cytokine-induced nitric oxide production in vascular smooth muscle cells. Endocrinology 140: 2183-2190. (Pubitemid 30636458)
18. Kleinert H, Pautz A, Linker K, Schwarz PM, (2004). Regulation of the expression of inducible nitric oxide synthase. Eur J Pharmacol 500: 255-266. (Pubitemid 39304013)
19. Krattenmacher R, (2000). Drosperinone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62: 29-38.
20. Lee WS, Harden JA, Yoshizami M, Lee ME, Haber E, (1997). Progesterone inhibits arterial smooth muscle cell proliferation. Nat Med 3: 1005-1008. (Pubitemid 27391955)
21. Leo JCL, Guo C, Woon CT, Aw SE, Lin VCL, (2004). Glucorticoid and mineralocorticoid cross-talk with progesterone receptor to induce focal adhesion and growth inhibition in breast cancer cells. Endocrinology 145: 1314-1321. (Pubitemid 38281015)
22. Matsumara M, Kakashita H, Suzuki M, Banba N, Hattori Y, (2001). Dexamethasone suppresses iNOS gene expression by inhibiting NF-κB in vascular smooth muscle cells. Life Sci 69: 1067-1077. (Pubitemid 32701917)
23. Molnar GA, Lindschau C, Dubrovska G, Mertens PR, Kirsch T, Quinkler M, et al,. (2008). Glucocorticoid-related signaling effects in vascular smooth muscle cells. Hypertension 51: 1372-1378. (Pubitemid 351555952)
24. Mosmann T, (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63. (Pubitemid 14203433)
25. Nichols NR, Nguyen HH, Meyer WJ, (1985). Physical separation of aortic corticoid receptors with type I and type II specificities. J Steroid Biochem 22: 577-582. (Pubitemid 15003140)
26. Pacher P, Beckman JS, Liaudet L, (2007). Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424. (Pubitemid 46217686)
27. Rebsamen MC, Perrier E, Gerber-Wicht C, Benitah J-P, Lang U, (2004). Direct and indirect effects of aldosterone on cyclooxygenase-2 and interleukin-6 expression in rat cardiac cells in culture and after myocardial infarction. Endocrinology 145: 3135-3142. (Pubitemid 38829982)
28. Robertson DAF, Hughes GA, Lyles GA, (2004). Expression of inducible nitric oxide synthase in cultured smooth muscle cells from rat mesenteric lymphatic vessels. Microcirculation 11: 503-515. (Pubitemid 39618626)
29. Rupprecht R, Reul JM, van Steensel B, Spengler D, Söder M, Berning B, et al,. (1993). Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol 247: 145-154. (Pubitemid 23309995)
30. Schiffrin EL, (2006). Effects of aldosterone on the vasculature. Hypertension 47: 312-318. (Pubitemid 43740260)
31. Shah AM, (2000). Inducible nitric oxide synthase and cardiovascular disease. Cardiovasc Res 45: 148-155.
32. Sønder SUS, Mikkelsen M, Rieneck K, Hedegaard CJ, Bendtzen K, (2006a). Effects of spironolactone on human blood mononuclear cells: mineralocorticoid receptor independent effects on gene expression and late apoptosis induction. Br J Pharmacol 148: 46-53. (Pubitemid 43675599)
33. Sønder SU, Woetmann A, Odum N, Bendtzen K, (2006b). Spironolactone induces apoptosis and inhibits NF-kappaB independent of the mineralocorticoid receptor. Apoptosis 11: 2159-2165. (Pubitemid 44885392)
34. Sorrentino L, Autore G, Cirino G, d'Emanuele de Villa Bianca R, Calignano A, Vanasia M, et al,. (2000). Effect of spironolactone and its metabolites on contractile property of isolated rat aorta rings. J Cardiovasc Pharmacol 36: 230-235. (Pubitemid 30659844)
35. Struthers A, Krum K, Williams GH, (2008). A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 31: 153-158. (Pubitemid 351556480)
36. Szabõ C, Mitchell JA, Gross SS, Thiemermann C, Vane JR, (1993). Nifedipine inhibits the induction of nitric oxide synthase by bacterial lipopolysaccharide. J Pharmacol Exp Ther 265: 674-680. (Pubitemid 23315573)
37. Titheradge MA, (1999). Nitric oxide in septic shock. Biochim Biophys Acta 1411: 437-455. (Pubitemid 29221966)
38. Toda M, Okamura T, (2003). The pharmacology of nitric oxide in the peripheral nervous system of blood vessels. Pharmacol Rev 55: 271-324. (Pubitemid 36666049)
39. Weber KT, (2001). Aldosterone in congestive heart failure. N Engl J Med 345: 1689-1697. (Pubitemid 33126826)
40. 2+ in vascular smooth muscle cells. Circ Res 76: 973-979.
41. Zancan V, Santagati S, Bolego C, Vegeto E, Maggi A, Puglisi L, (1999). 17Beta- estradiol decreases nitric oxide synthase II synthesis in vascular smooth muscle cells. Endocrinology 140: 2004-2009. (Pubitemid 30636436)
42. Zhou J, Struthers AD, Lyles GA, (1999). Differential effects of some cell signalling agents upon nitric oxide synthase expression and nuclear factor-κB activation induced by lipopolysaccharide in rat aortic smooth muscle cells. Pharmacol Res 39: 363-373. (Pubitemid 29263904)